Celgene Corp.'s Revlimid, in combination with rituximab, failed to meet its primary goal in a phase 3 trial in patients with follicular lymphoma, a cancer of the white blood cells.
Rituximab is sold by Roche Holding AG as Rituxan or MabThera for treating chronic lymphocytic leukemia and various types of non-Hodgkin's lymphoma.
The study evaluated treatment by Revlimid plus rituximab followed by maintenance compared to the standard of care with rituximab plus chemotherapy followed by rituximab maintenance in patients with previously untreated follicular lymphoma.
Celgene said the Revlimid combination did not achieve superiority in the co-primary endpoints of complete response or unconfirmed complete response at 120 weeks and progression-free survival during the pre-planned analysis.
While a complete response means disappearance of all signs of cancer after treatment, progression-free survival refers to the duration for which the disease does not get worse.
The study, conducted by Celgene and the Lymphoma Study Association, also showed that neither arm was superior for either of the co-primary endpoints.
Revlimid is currently approved for several indications including treating multiple myeloma and mantle cell lymphoma, both of which are cancers of the white blood cells.